LNTH - Lantheus Holdings, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.48
-1.17 (-7.99%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close14.65
Open14.44
Bid10.65 x 800
Ask13.75 x 2200
Day's Range13.13 - 14.46
52 Week Range8.67 - 27.12
Volume1,600,707
Avg. Volume686,817
Market Cap900.274M
Beta (5Y Monthly)1.24
PE Ratio (TTM)47.46
EPS (TTM)0.28
Earnings DateJul 30, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-17% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Lantheus Holdings Inc (LNTH) Q2 2020 Earnings Call Transcript
    Motley Fool

    Lantheus Holdings Inc (LNTH) Q2 2020 Earnings Call Transcript

    Joining me today is our President and CEO, Mary Anne Heino, and our CFO, Bob Marshall. Before we get started, I'd like to remind you that our comments during this call will include forward-looking statements. Actual results may differ materially from those indicated by forward-looking statements due to a variety of risks and uncertainties.

  • Lantheus Holdings, Inc. Reports Second Quarter 2020 Financial Results
    Business Wire

    Lantheus Holdings, Inc. Reports Second Quarter 2020 Financial Results

    Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today reported financial results for its second quarter ended June 30, 2020.

  • Did Hedge Funds Make The Right Call On Lantheus Holdings Inc (LNTH) ?
    Insider Monkey

    Did Hedge Funds Make The Right Call On Lantheus Holdings Inc (LNTH) ?

    We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]

  • Lantheus Holdings to Host Second Quarter 2020 Earnings Conference Call on July 30, 2020 at 8:00 a.m. Eastern Time
    Business Wire

    Lantheus Holdings to Host Second Quarter 2020 Earnings Conference Call on July 30, 2020 at 8:00 a.m. Eastern Time

    Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Thursday, July 30, 2020, to discuss its financial and operating results for the second quarter of 2020.

  • Lantheus Holdings to Showcase the Potential of PyL™ Imaging Agent at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting
    Business Wire

    Lantheus Holdings to Showcase the Potential of PyL™ Imaging Agent at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting

    Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced that 17 abstracts highlighting PyL™ (18F-DCFPyL) have been selected for presentation at the virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting taking place July 11-14, 2020. PyL is the PSMA-targeted small molecule positron emission tomography (PET) imaging investigational agent designed to visualize prostate cancer, which the Company recently purchased as part of the oncology business of Progenics.

  • Lantheus Holdings Inc (LNTH): Hedge Funds Are Adding
    Insider Monkey

    Lantheus Holdings Inc (LNTH): Hedge Funds Are Adding

    The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

  • Lantheus Completes Merger with Progenics
    Business Wire

    Lantheus Completes Merger with Progenics

    Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that it has completed its previously announced merger with Progenics Pharmaceuticals, Inc. ("Progenics") (Nasdaq: PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer. The merger agreement was first announced on October 2, 2019.

  • Independent Bank Group Set to Join S&P SmallCap 600
    PR Newswire

    Independent Bank Group Set to Join S&P SmallCap 600

    Independent Bank Group Inc. (NASD: IBTX) will replace Progenics Pharmaceuticals Inc. (NASD: PGNX) in the S&P; SmallCap 600 effective prior to the opening of trading on Monday, June 22. S&P; Small-Cap 600 constituent Lantheus Holdings Inc. (NASD: LNTH) is acquiring Progenics Pharmaceuticals in a deal expected to be completed on or about June 19 pending final conditions. Post-acquisition, Lantheus Holdings will remain in S&P; SmallCap 600.

  • Lantheus Stockholders Approve Share Issuance For Merger with Progenics
    Business Wire

    Lantheus Stockholders Approve Share Issuance For Merger with Progenics

    Lantheus Holdings, Inc. (NASDAQ: LNTH) ("Lantheus" or the "Company"), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents announced that at a special meeting held earlier today, Lantheus’ stockholders voted to approve the issuance of common stock related to the Company’s proposed merger with Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) ("Progenics"), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer.

  • Lantheus Holdings to Present at the BMO 2020 Prescriptions for Success Virtual Healthcare Conference
    Business Wire

    Lantheus Holdings to Present at the BMO 2020 Prescriptions for Success Virtual Healthcare Conference

    Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced Mary Anne Heino, President and Chief Executive Officer, will present at the BMO 2020 Prescriptions for Success Virtual Healthcare Conference at 3:30 p.m. ET on Tuesday, June 23.

  • SHAREHOLDER ALERT: WeissLaw LLP Investigates Progenics Pharmaceuticals, Inc.
    PR Newswire

    SHAREHOLDER ALERT: WeissLaw LLP Investigates Progenics Pharmaceuticals, Inc.

    WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company") (NASDAQ: PGNX) in connection with the proposed acquisition of the company by Lantheus Holdings, Inc. ("LNTH") (NASDAQ: LNTH). Under the terms of the acquisition agreement, PGNX shareholders will receive 0.31 shares of LNTH for each PGNX share they own, representing implied per-share merger consideration of only $3.96 based on LNTH's May 26, 2020 closing price of $12.77.

  • Lantheus Holdings to Present at the Jefferies Virtual Healthcare Conference
    Business Wire

    Lantheus Holdings to Present at the Jefferies Virtual Healthcare Conference

    Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced Mary Anne Heino, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference at 10:30 a.m. ET on Wednesday, June 3.

  • Lantheus Holdings to Present at the UBS Virtual Global Healthcare Conference
    Business Wire

    Lantheus Holdings to Present at the UBS Virtual Global Healthcare Conference

    Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced Mary Anne Heino, President and Chief Executive Officer, will present at the UBS Virtual Global Healthcare Conference at 3:00 p.m. ET on Tuesday, May 19.

  • Thomson Reuters StreetEvents

    Edited Transcript of LNTH earnings conference call or presentation 30-Apr-20 12:00pm GMT

    Q1 2020 Lantheus Holdings Inc Earnings Call

  • Lantheus Holdings Inc (LNTH) Q1 2020 Earnings Call Transcript
    Motley Fool

    Lantheus Holdings Inc (LNTH) Q1 2020 Earnings Call Transcript

    Image source: The Motley Fool. Lantheus Holdings Inc (NASDAQ: LNTH)Q1 2020 Earnings CallApr 30, 2020, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning, ladies and gentlemen.

  • Benzinga

    Recap: Lantheus Holdings Q1 Earnings

    Shares of Lantheus Holdings (NASDAQ:LNTH) remained unaffected at $14.03 after the company reported Q1 results.Quarterly Results Earnings per share rose 28.57% over the past year to $0.36, which beat the estimate of $0.27.Revenue of $90,704,000 rose by 4.85% year over year, which missed the estimate of $91,200,000.Guidance Lantheus Holdings hasn't issued any earnings guidance for the time being.Lantheus Holdings hasn't issued any revenue guidance for the time being.Details Of The Call Date: Apr 30, 2020View more earnings on LNTHTime: 12:02 PM ETWebcast URL: https://edge.media-server.com/mmc/p/dj4madogTechnicals 52-week high: $29.80Company's 52-week low was at $8.67Price action over last quarter: down 13.93%Company Profile Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its imaging products and agents assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging used by physicians to progress the clarity of the diagnostic image. The company's portfolio of imaging products includes medical radiopharmaceuticals such as DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, and Neurolite. Its revenue is generated from the sales of diagnostic imaging agents to wholesalers, distributors radiopharmacy and directly to hospitals and clinics predominantly in the United States.See more from Benzinga * Amalgamated Bank: Q1 Earnings Insights * 15 Consumer Cyclical Stocks Moving In Thursday's Pre-Market Session * 9 Real Estate Stocks Moving In Thursday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Lantheus Holdings, Inc. Reports First Quarter 2020 Financial Results
    Business Wire

    Lantheus Holdings, Inc. Reports First Quarter 2020 Financial Results

    Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today reported financial results for its first quarter ended March 31, 2020.

  • Lantheus Holdings to Host First Quarter 2020 Earnings Conference Call on April 30, 2020 at 8:00 a.m. Eastern Time
    Business Wire

    Lantheus Holdings to Host First Quarter 2020 Earnings Conference Call on April 30, 2020 at 8:00 a.m. Eastern Time

    Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Thursday, April 30, 2020, to discuss its financial and operating results for the first quarter of 2020.

  • ADDING MULTIMEDIA Velan Capital Agrees to Support Merger of Lantheus and Progenics
    Business Wire

    ADDING MULTIMEDIA Velan Capital Agrees to Support Merger of Lantheus and Progenics

    Lantheus Holdings, Inc. (NASDAQ: LNTH) ("Lantheus"), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) ("Progenics"), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that Lantheus has entered into a Support Agreement (the "Support Agreement") with Velan Capital ("Velan") in connection with the proposed merger of Lantheus and Progenics.

  • Lantheus Holdings, Inc. Reports Preliminary Q1 Revenue Near Top End of Previously Disclosed Guidance Range; Withdraws 2020 Financial Guidance
    Business Wire

    Lantheus Holdings, Inc. Reports Preliminary Q1 Revenue Near Top End of Previously Disclosed Guidance Range; Withdraws 2020 Financial Guidance

    Lantheus Holdings, Inc. (NASDAQ: LNTH) ("Lantheus" or the "Company"), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents announced today that its preliminary unaudited revenue for the fiscal first quarter ended March 31, 2020 will be near the top end of previously disclosed guidance range issued on February 25, 2020.

  • Lantheus Holdings, Inc. to Hold 2020 Annual Meeting of Stockholders Virtually
    Business Wire

    Lantheus Holdings, Inc. to Hold 2020 Annual Meeting of Stockholders Virtually

    In response to continued public health concerns about in-person gatherings given the coronavirus/COVID-19 outbreak, the Board of Directors of Lantheus Holding, Inc. (the "Company") (NASDAQ:LNTH) has determined to change the format of the company’s 2020 Annual Meeting of Stockholders scheduled for Thursday, April 23, 2020 at 11:00 a.m. (Eastern Time) from in-person to virtual-only.

  • How Does Lantheus Holdings's (NASDAQ:LNTH) P/E Compare To Its Industry, After The Share Price Drop?
    Simply Wall St.

    How Does Lantheus Holdings's (NASDAQ:LNTH) P/E Compare To Its Industry, After The Share Price Drop?

    To the annoyance of some shareholders, Lantheus Holdings (NASDAQ:LNTH) shares are down a considerable 31% in the last...

  • Boston Scientific cuts exec pay as revenue slides
    American City Business Journals

    Boston Scientific cuts exec pay as revenue slides

    Boston Scientific Corp. became one of the first local medical device firms to cut executive and employee pay as the COVID-19 outbreak cuts into surgical product sales.

  • Lantheus and Progenics Reschedule Their Respective Special Meetings of Stockholders for Proposed Merger
    Business Wire

    Lantheus and Progenics Reschedule Their Respective Special Meetings of Stockholders for Proposed Merger

    Lantheus Holdings, Inc. (NASDAQ: LNTH) ("Lantheus"), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) ("Progenics"), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that they have decided to reschedule their respective special meetings of stockholders (the "Special Meetings") to vote on matters related to the proposed merger of Lantheus and Progenics from April 28, 2020, to June 16, 2020.